UR-144 is a potent synthetic cannabinoid designed by Abbott Laboratories as a CB2 selective agonist for pain management and other indications. UR-144 preferentially binds the peripheral CB2 receptor (Ki = 1.8 nM) over the central CB1 receptor (Ki = 150 nM). Pre-clinical studies of nociceptive and neuropathic pain have shown that CB2-selective ligands are analgesics without causing the adverse side effects linked with CB1 receptor activation. However, UR-144 has no therapeutic application. According to the FDA (US Food and Drug Administration) there are currently no approved or on-going drug applications for the medical use of UR-144.

JWH-073, a synthetic cannabinoid, is an analgesic chemical from the naphthoylindole family that acts as a neutral antagonist of CB1 cannabioid receptor and binder of CB2 cannabinoid receptor. JWH-073 is being used as a recreational drug in Spice products, and is a controlled substance in USA.